These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33817720)

  • 1. Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?
    Strobescu-Ciobanu C; Giuşcă SE; Căruntu ID; Amălinei C; Rusu A; Cojocaru E; Popa RF; Lupaşcu CD
    Rom J Morphol Embryol; 2020; 61(3):793-801. PubMed ID: 33817720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.
    Kadoglou NP; Gerasimidis T; Golemati S; Kapelouzou A; Karayannacos PE; Liapis CD
    J Vasc Surg; 2008 Jan; 47(1):55-62. PubMed ID: 18178454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
    J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.
    Higgins CL; Isbilir S; Basto P; Chen IY; Vaduganathan M; Vaduganathan P; Reardon MJ; Lawrie G; Peterson L; Morrisett JD
    Protein J; 2015 Oct; 34(5):315-28. PubMed ID: 26307009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability.
    Straface G; Biscetti F; Pitocco D; Bertoletti G; Misuraca M; Vincenzoni C; Snider F; Arena V; Stigliano E; Angelini F; Iuliano L; Boccia S; de Waure C; Giacchi F; Ghirlanda G; Flex A
    Stroke; 2011 Nov; 42(11):3022-8. PubMed ID: 21903966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients.
    Wolak T; Sion-Vardi N; Novack V; Greenberg G; Szendro G; Tarnovscki T; Nov O; Shelef I; Paran E; Rudich A
    Am J Hypertens; 2013 Mar; 26(3):326-33. PubMed ID: 23382482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
    Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods.
    Basiak M; Hachula M; Kosowski M; Machnik G; Maliglowka M; Dziubinska-Basiak M; Krysiak R; Okopien B
    Molecules; 2023 Aug; 28(15):. PubMed ID: 37570897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans.
    Vik A; Mathiesen EB; Notø AT; Sveinbjørnsson B; Brox J; Hansen JB
    Atherosclerosis; 2007 Mar; 191(1):128-34. PubMed ID: 16620835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
    Kadoglou NP; Gerasimidis T; Moumtzouoglou A; Kapelouzou A; Sailer N; Fotiadis G; Vitta I; Katinios A; Kougias P; Bandios S; Voliotis K; Karayannacos PE; Liapis CD
    Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):661-8. PubMed ID: 18395477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Concentrations of New Biochemical Markers of Atherosclerosis in Patients with Dyslipidemia-A Pilot Study.
    Kosowski M; Basiak M; Hachuła M; Okopień B
    Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.
    Tousoulis D; Siasos G; Maniatis K; Oikonomou E; Kioufis S; Zaromitidou M; Paraskevopoulos T; Michalea S; Kollia C; Miliou A; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 167(5):1924-8. PubMed ID: 22640692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of osteopontin, and osteoprotegerin mRNA in epicardial adipose tissue between patients with severe coronary artery disease and aortic valvular stenosis: association with HDL subclasses.
    Luna-Luna M; Cruz-Robles D; Ávila-Vanzzini N; Herrera-Alarcón V; Martínez-Reding J; Criales-Vera S; Sandoval-Zárate J; Vargas-Barrón J; Martínez-Sánchez C; Tovar-Palacio AR; Fragoso JM; Carreón-Torres E; Vargas-Alarcón G; Pérez-Méndez Ó
    Lipids Health Dis; 2017 Aug; 16(1):156. PubMed ID: 28821297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of NPP1 is regulated during atheromatous plaque calcification.
    Nitschke Y; Hartmann S; Torsello G; Horstmann R; Seifarth H; Weissen-Plenz G; Rutsch F
    J Cell Mol Med; 2011 Feb; 15(2):220-31. PubMed ID: 20015201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients].
    Czyzewska-Buczyńska A; Zuk N; Bałasz S; Witkiewicz W
    Przegl Lek; 2013; 70(3):102-5. PubMed ID: 24003660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease.
    Kadoglou NPE; Kapetanios D; Korakas E; Valsami G; Tentolouris N; Papanas N; Lambadiari V; Karkos C
    Cardiovasc Diabetol; 2022 Sep; 21(1):171. PubMed ID: 36050687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
    Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
    J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
    Davaine JM; Quillard T; Brion R; Lapérine O; Guyomarch B; Merlini T; Chatelais M; Guilbaud F; Brennan MÁ; Charrier C; Heymann D; Gouëffic Y; Heymann MF
    PLoS One; 2014; 9(9):e107642. PubMed ID: 25259713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.
    Golledge J; McCann M; Mangan S; Lam A; Karan M
    Stroke; 2004 Jul; 35(7):1636-41. PubMed ID: 15143295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.